TITLE

GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT

PUB. DATE
February 2009
SOURCE
Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray would be used for the treatment of adults and children with Type-1 or Type-2 diabetes mellitus.
ACCESSION #
36237376

 

Related Articles

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • Noninjectable Insulins Win Approval: Pfizer in the US, Generex in South America. Koroneos, George // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p28 

    The article reports on the approval of noninjectable insulins in the United States and in South America. Pfizer's Exubera has been approved by the U.S. Food and Drug Administration to treat adults with type 1 and type 2 diabetes. Generex's oral insulin "Oral-lyn" went on the market in Ecuador...

  • Rapid- and slow-acting insulins help control diabetes. Zablocki, Elaine // Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p46 

    The article enlightens about the availability of two rapid-acting insulins with a more rapid onset and shorter duration of action than regular insulin to contain blood sugar levels in people with diabetes, whose population is increasing at an alarming rate in the United States. Byetta is a new...

  • life sciences In Brief.  // Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8 

    The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports...

  • GENEREX EXPANDS PLAN FOR FDA IND FOR ORAL-LYN.  // Biotech Business;May2010, Vol. 23 Issue 5, p3 

    The article reports the move of Generex Biotechnology Corp. to include licensed and qualified nurse practitioners in plans for its U.S. Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for its oral insulin Generex Oral-lyn. Under the program,...

  • New Inhalable Insulin Getting Ready for Clinical Trials.  // Diabetes Health;Sep2006, Vol. 15 Issue 9, p18 

    The article reports on the agreement of Generex Biotechnology Corp. with Cardinal Health Inc. to manufacture clinical trial batches of Generex Oral-Lyn inhalable insulin spray. The agreement is announced on June 22, 2006. Generex Oral-Lyn inhalable insulin spray is already available in Ecuador.

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4 

    The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lyn� at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1...

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics